December 13, 2016
Eli Lilly announces dividend increase
The board of directors of Eli Lilly has announced a 2 percent increase in its quarterly dividend. The dividend for…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 13, 2016
Short: Active Biotech’s rights issue completed
Active Biotech has announced on Tuesday that following the end of the subscription period, the results of Active Biotech’s rights issue…
December 13, 2016
Monsanto shareowners approve merger with Bayer
Shareowners of the Monsanto Company have approved the merger of Monsanto with a wholly owned subsidiary of Bayer Aktiengesellschaft.
December 13, 2016
Zealand Pharma increases share capital
Zealand Pharma has on Monday increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a…
December 13, 2016
Short: Active Biotech completes issuing rights, share capital up by €2,7M
The results of Active Biotech’s rights issue show that 6,643,426 shares, which is about 96 percent of the shares offered,…
December 13, 2016
Type 2 diabetes gets new treatment in U.S., FDA OKs Boehringer’s Synjardy XR
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Synjardy XR tablets for adults with type 2 diabetes.…
December 12, 2016
Bayer and Versant Ventures to launch BlueRock Therapeutics
Bayer AG and Versant Ventures have announced the launch of BlueRock Therapeutics, a next-generation regenerative medicine company that plans to…
December 12, 2016
Novartis’s Monaleesa study show PFS in breast cancer treatment
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…
December 12, 2016
Achaogen passes US and European hurdles to market its plazomicin antibiotic
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
December 12, 2016
Alvogen’s flu capsules alternative for Tamiflu
Alvogen on Monday launched the first flu capsules, generic equivalent to Roche’s Tamiflu (oseltamivir phosphate) capsules in the United States.